GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Paliperidone palmitate - INVEGA HAFYERA six-month injection

Local official-label summaryBase record retrieved 2026-09-08See the evidence for this drug2 sources available - open source summaries, references and comparisons

INVEGA HAFYERA / INVEGA HAFYERA injection / paliperidone palmitate

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
HAFYERA: general renal and geriatric sections must both be read

The geriatric renal restriction is more restrictive than the general adult mild-impairment pathway. This distinction is present in both the RX mirror and official label, not merely one rendering.

Before applying: Do not silently override the age-specific statement. Seek product-label/pharmacy or manufacturer clarification before applying a general adult pathway to an elderly patient with renal impairment.

Also check: HAFYERA: general renal and geriatric sections must both be read

Official source

Paliperidone palmitate - INVEGA HAFYERA six-month injection

Product / population
Adults; INVEGA HAFYERA six-month intramuscular suspension. Read the separate geriatric limitation before applying general adult guidance.
Renal measure
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.

An instructions-for-use revision is a separate document date. No geriatric regimen is chosen by this tool.

Renal dosing, restrictions and evidence limits

Sections 2.4 and 8.6 allow the specified prior-product adjustment and stabilization pathway for CrCl 50 to <80, but not use at CrCl <50. Section 8.5 separately states that HAFYERA is not recommended in elderly patients with mild, moderate or severe renal impairment. Both statements occur in this official label; this is not merely a mirror discrepancy. Age-specific eligibility requires clarification rather than automatic application of the general adult pathway.

Source revision: Prescribing information revised 01/2025. | Retrieved: 2026-09-08. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cd61892-d2cb-434d-83ed-5c1b2c4e7a0b

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Paliperidone palmitate - INVEGA HAFYERA six-month injection

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adults; INVEGA HAFYERA six-month intramuscular suspension. Read the separate geriatric limitation before applying general adult guidance.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Retrieved: 2026-09-08

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - INVEGA HAFYERA

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adults; INVEGA HAFYERA six-month intramuscular suspension. Read the separate geriatric limitation before applying general adult guidance.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

population scope

HAFYERA: general renal and geriatric sections must both be read

The geriatric renal restriction is more restrictive than the general adult mild-impairment pathway. This distinction is present in both the RX mirror and official label, not merely one rendering.

How to use this: Do not silently override the age-specific statement. Seek product-label/pharmacy or manufacturer clarification before applying a general adult pathway to an elderly patient with renal impairment.

GlobalRPh RX List - INVEGA HAFYERAPaliperidone palmitate - INVEGA HAFYERA six-month injectionPaliperidone palmitate - INVEGA SUSTENNA monthly injectionPaliperidone palmitate - INVEGA TRINZA three-month injection

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopePaliperidone palmitate - INVEGA HAFYERA six-month injectionGlobalRPh RX List - INVEGA HAFYERA
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/invega-hafyera-drug/

Exact product and population

Adults; INVEGA HAFYERA six-month intramuscular suspension. Read the separate geriatric limitation before applying general adult guidance.

RDM44-SCOPE-paliperidone-invega-hafyera · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Paliperidone palmitate - INVEGA HAFYERA six-month injection

Open original reference

Open / share this exact local source

DailyMed / Janssen Pharmaceuticals, Inc. · Adults; INVEGA HAFYERA six-month intramuscular suspension. Read the separate geriatric limitation before applying general adult guidance.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Source date: Prescribing information revised 01/2025.
Retrieved: 2026-09-08

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Sections 2.4 and 8.6 allow the specified prior-product adjustment and stabilization pathway for CrCl 50 to <80, but not use at CrCl <50. Section 8.5 separately states that HAFYERA is not recommended in elderly patients with mild, moderate or severe renal impairment. Both statements occur in this official label; this is not merely a mirror discrepancy. Age-specific eligibility requires clarification rather than automatic application of the general adult pathway.

RDM44-official-paliperidone-invega-hafyera-ac61130f88-C1 · Source locator: Sections 2.4, 8.5 and 8.6; PI revision 1/2025.

Source-specific limits

An instructions-for-use revision is a separate document date. No geriatric regimen is chosen by this tool.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cd61892-d2cb-434d-83ed-5c1b2c4e7a0b
Retrieved
2026-09-08
Exact label title
Paliperidone palmitate - INVEGA HAFYERA six-month injection
DailyMed Set ID
6cd61892-d2cb-434d-83ed-5c1b2c4e7a0b
Labeler
Janssen Pharmaceuticals, Inc.
Label revision
Prescribing information revised 01/2025.
Renal-function method
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Source date/version
Prescribing information revised 01/2025.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
67b4d942f03cf87884c0c72f1d9a5d836535a14ed152fa7a9cec2b2b3e9ef64a
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - INVEGA HAFYERA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adults; INVEGA HAFYERA six-month intramuscular suspension. Read the separate geriatric limitation before applying general adult guidance.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

General renal guidance permits CrCl 50 to <80 only after adjustment and stabilization on the one-month product, with the specified transition pathway; CrCl <50 is not recommended. Separately, the geriatric section says use is not recommended in elderly patients with mild, moderate or severe renal impairment. The age-specific restriction is retained, not overridden by the general section.

RDM44-rxlist-paliperidone-invega-hafyera-fd6a86a2e9-C1 · Source locator: Dosage and Administration: Renal impairment, lines 104-107; Geriatric Use and Renal Impairment, lines 759-762.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/invega-hafyera-drug/
Retrieved
2026-09-08
Renal-function method
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
e8c33a3aad455354f0bfe36619961148c24cb80354e6aba3471cdf863c7ff337

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/invega-hafyera-drug/
Source retrieval
2026-09-08. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
a1c3a999cf1f3437953f7dab2466f8d9ae0d1e2b58de8aeb51e244ded5ba84b9
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report